While capital expenditures remain low at approximately 0.7% of revenue, cash flow volatility persists, as evidenced by the OCF/NI ratio swinging from -24.84 in 2023Q4 to 0.83 in 2026Q1.
| Cash from Operations | 511.51M | 490.17M | 23.77M | 210.78M | -4.65M | 270.17M | 222.64M | 110.91M |
| Operating CF Margin % | - | 3.8% | 0.21% | 2.39% | -0.06% | 4.03% | 3.99% | 2.45% |
| Operating CF Growth % | 895.05% | 1961.79% | -88.72% | 4630.05% | -101.72% | 21.35% | 100.74% | - |
| Net Income | 309.89M | 190.67M | -20.52M | -156.84M | -54.22M | 51.26M | 21.15M | -71.09M |
| Depreciation & Amortization | 161.21M | 164.28M | 204.48M | 202.34M | 203.97M | 199.16M | 181.5M | 154.87M |
| Stock-Based Compensation | 58.09M | 70.1M | 69.17M | 3.92M | 3.55M | 4.52M | 6.27M | 3.71M |
| Deferred Taxes | -4.03M | 0 | -25.91M | -52.63M | -27.96M | 6.49M | 22.6M | -34.41M |
| Other Non-Cash Items | -600K | 83.67M | 66.63M | 54.56M | 94.48M | 38.85M | 27.2M | 64.31M |
| Working Capital Changes | -13.43M | -18.54M | -270.07M | 159.44M | -224.47M | -30.11M | -36.08M | -6.48M |
| Change in Receivables | -165.96M | -131.29M | -179.04M | -127.25M | -150.47M | -93M | -58.91M | -53.95M |
| Change in Inventory | -26.37M | -177.91M | -236.51M | 28.66M | -131.83M | 4.29M | -95.73M | -16.03M |
| Change in Payables | 231.06M | 264.17M | 303.21M | 105.65M | 133.47M | 63.54M | 100.43M | 46.78M |
| Cash from Investing | 466.5M | -310.18M | -140.24M | -134.43M | 45.36M | -1.19B | -452.87M | -1.53B |
| Capital Expenditures | -3.91M | 0 | -80.91M | -73.53M | -70.11M | -59.27M | -51.91M | -51.22M |
| CapEx % of Revenue | 0.03% | 0.74% | 0.72% | 0.83% | 0.91% | 0.88% | 0.93% | 1.13% |
| Acquisitions | -35.45M | 0 | -59.8M | -63.06M | 113.33M | -1.13B | -402.01M | -1.48B |
| Investments | - | - | - | - | - | - | - | - |
| Other Investing | 505.87M | -310.18M | 473K | 2.15M | 2.13M | 1.7M | 1.05M | 1.41M |
| Cash from Financing | -141.86M | -152.77M | 164.65M | -76.91M | -73.81M | 705.22M | 473.94M | 1.41B |
| Debt Issued (Net) | 78.5M | -127.12M | -829.36M | -66.14M | -68.93M | 726.86M | 493.17M | 1.27B |
| Equity Issued (Net) | -32.57M | -17.89M | 1.04B | -650K | 0 | 12.39M | -1.12M | 261.14M |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Share Repurchases | -103.17M | -43.17M | -650K | -650K | 0 | -417K | -1.12M | -12.29M |
| Other Financing | -187.79M | -7.75M | -50.83M | -10.12M | -4.88M | -34.03M | -18.11M | -118.59M |
| Net Change in Cash | 837M | 27.12M | 48.18M | -557K | -33.11M | -215.27M | 243.71M | -12.23M |
| Free Cash Flow | 507.6M | 394.69M | -57.14M | 137.26M | -74.77M | 210.9M | 170.73M | 59.69M |
| FCF Margin % | 3.72% | 3.06% | -0.51% | 1.56% | -0.97% | 3.15% | 3.06% | 1.32% |
| FCF Growth % | 298.11% | 790.75% | -141.63% | 283.58% | -135.45% | 23.52% | 186.03% | - |
| FCF per Share | 2.29 | 1.80 | -0.30 | 0.80 | -0.44 | 1.23 | 1.00 | 0.35 |
| FCF Conversion (FCF/Net Income) | 1.64x | 2.57x | -1.32x | -1.36x | 0.09x | 5.43x | 10.70x | -1.53x |
| Interest Paid | -53.8M | 183.51M | 211.39M | 303.53M | 213.31M | 126.95M | 129.57M | 134.38M |
| Taxes Paid | -245K | 26.97M | 24.95M | 37.5M | 28.85M | 0 | 3M | 3.72M |
Working capital volatility
As reported in recent financial statements, the relationship between net income and operating cash flow is inconsistent, with the OCF/NI ratio fluctuating wildly from -24.84 in 2023Q4 to 5.66 in 2024Q4, indicating that GAAP earnings are currently poor proxies for the company's actual cash-generative capacity.
The significant divergence between net income and operating cash flow suggests that non-cash charges and working capital swings are heavily distorting the bottom line. Investors should monitor whether this volatility is a structural byproduct of Medicaid billing cycles or indicative of underlying accounting adjustments that mask operational cash flow stability.
Based on the provided cash flow data, working capital changes have been a major source of volatility, ranging from a $121.9 million inflow in 2023Q4 to a $99.9 million outflow in 2024Q1, highlighting the sensitivity of the company's cash position to the timing of government reimbursement receipts.
The erratic nature of these working capital movements suggests that the company's cash flow is highly susceptible to administrative delays in the Medicaid and Medicare billing process. This lack of predictability in cash conversion cycles may necessitate higher liquidity buffers than the current balance sheet might otherwise suggest.
According to the company's quarterly filings, capital expenditures as a percentage of revenue have remained consistently low, averaging approximately 0.7% over the last ten quarters, which suggests that the business model is not capital-intensive in terms of physical asset maintenance or infrastructure replacement requirements.
The low capital intensity implies that the company's primary growth engine is inorganic acquisition rather than internal capacity expansion. While this preserves cash, it also suggests that the firm's competitive moat is not built on proprietary physical infrastructure, but rather on the integration of acquired service networks.
As evidenced by the recent cash flow data, the company has prioritized significant capital deployment toward share repurchases, including a $60.0 million outflow in 2026Q1, alongside ongoing net acquisition activity, which collectively compete with the firm's ability to retain cash for deleveraging or operational contingencies.
The decision to allocate substantial cash to share repurchases while operating with thin net margins warrants further investigation into management's long-term capital priorities. This strategy appears to favor immediate shareholder returns over building a more robust cash cushion to mitigate the inherent risks of the healthcare services sector.
Quick answers to the most common questions about buying BTSG stock.
BrightSpring Health Services, Inc. Common Stock (BTSG) generated $490.2M in net cash from operating activities in 2025. This reflects the cash generated directly from core business operations.
BrightSpring Health Services, Inc. Common Stock (BTSG) generated $394.7M in free cash flow in 2025. Free cash flow is the cash left over after capital expenditures, which can be used to pay dividends, repurchase shares, or pay down debt.
BrightSpring Health Services, Inc. Common Stock (BTSG) spent $0.0M on capital expenditures in 2025. CapEx represents the cash invested in physical assets like property, plant, and equipment to maintain or grow the business.
In 2025, BrightSpring Health Services, Inc. Common Stock (BTSG) spent $43.2M on share repurchases. This shows the company's commitment to returning capital to its equity investors.